SMARCA4 and acute myeloid leukemia: Inhibition of BRD9 resulted in a reduction in accessibility at GATA, AP-1, and ETS motifs, as well as significantly reduced occupancy of BRD9 and BRG1 at AML-specific enhancers, such as Myc, resulting in a strong reduction in chromatin accessibility at enhancers and promoters and enhancer RNA transcription [68].